2-isopropyl-2-nitro-1,3-propanediol | 62155-31-1

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 2-isopropyl-2-nitro-1,3-propanediol
• 英文别名: 2-isopropyl-2-nitro-propane-1,3-diol；2-Isopropyl-2-nitro-propan-1,3-diol；2-Nitro-3-methyl-2-hydroxymethyl-butanol-(1)；2-Nitro-2-isopropyl-1,3-propanediol；2-nitro-2-propan-2-ylpropane-1,3-diol
• CAS: 62155-31-1
• 化学式: C₆H₁₃NO₄
• 分子量: 163.174
• InChiKey: UREFUUVULNQGAM-UHFFFAOYSA-N

物化性质

• 熔点：
  84-86 °C
• 沸点：
  320.6±32.0 °C(Predicted)
• 密度：
  1.201±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  86.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-isopropyl-2-nitro-1,3-propanediol 在 镍 三氟化硼乙醚 、 氢气 作用下， 以 乙醇 为溶剂， 40.0~70.0 ℃ 、10.64 kPa 条件下， 反应 2.58h， 生成 5-异丙基-2,2-二甲基-1,3-二恶烷-5-胺
  参考文献：
  名称：

  Kraiz, B. O.; Shenberg, N. N.; Ivin, B. A., Journal of Organic Chemistry USSR (English Translation), 1985, vol. 21, # 2, p. 379 - 386

  摘要：

  DOI：
• 作为产物：
  描述：

  2-甲-1-硝丙烷 生成 2-isopropyl-2-nitro-1,3-propanediol
  参考文献：
  名称：

  BAIR, KENNETH W.

  摘要：

  DOI：

文献信息

• Fluoranthene derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04720587A1

  公开（公告）日：1988-01-19

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a fluoranthene or substituted fluoranthene ring system; R.sup.1 contains not more than eight carbon carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物的公式（I）ArCH.sub.2 R.sup.1（I）或其单甲基或单乙基醚（公式（I）的化合物包括这些醚，在总共不超过30个碳原子）；醚，酯；酸盐；其中Ar是氟蒽或取代的氟蒽环系统；R.sup.1含有不超过八个碳原子，并且是一个基团##STR1##其中m为0或1；R.sup.5为氢；R.sup.6和R.sup.7相同或不同，每个是氢或C.sub.1-3烷基，可选择地被羟基取代；R.sup.8和R.sup.9相同或不同，每个是氢或C.sub.1-3烷基；##STR2##是一个五元或六元饱和碳环；R.sup.10为氢，甲基或羟甲基；R.sup.11，R.sup.12和R.sup.13相同或不同，每个是氢或甲基；R.sup.14为氢，甲基，羟基或羟甲基。
• Phenanthro[2,3-6]thiophene derivatives, pharmaceutical compositions and
  申请人：Burroughs Wellcome Co.

  公开号：US04910218A1

  公开（公告）日：1990-03-20

  The present invention relates to anti tumor compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 29 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a fused tetracyclic aromatic ring system comprised of 5-membered and 6-membered rings and contains at least one heteroatom and 3 aromatic rings and a total of no more than 18 ring atoms, or a substituted derivative thereof; the heteroatom is preferably oxygen, sulfur or nitrogen; when it is nitrogen this is substituted by hydrogen, methyl or ethyl; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-5 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及式（I）ArCH.sub.2 R.sup.1（I）或其单甲基或单乙基醚（式（I）的化合物包括这些醚，总碳原子数不超过29）的抗肿瘤化合物；它们的醚，酯；酸加成盐；其中Ar是由5元环和6元环组成的融合四环芳香环系统，并含有至少一个杂原子和3个芳香环，总环原子数不超过18，或其取代衍生物；杂原子最好是氧、硫或氮；当它是氮时，被氢、甲基或乙基取代；R.sup.1含有不超过八个碳原子，是一个组##STR1##其中m为0或1；R.sup.5为氢；R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-5烷基，可选择地被羟基取代；R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基；##STR2##是一个五元或六元饱和碳环；R.sup.10为氢、甲基或羟甲基；R.sup.11、R.sup.12和R.sup.13相同或不同，每个都是氢或甲基；R.sup.14为氢、甲基、羟基或羟甲基。
• Crysene derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04719046A1

  公开（公告）日：1988-01-12

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a chrysene or substituted chrysene ring system; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl, ##STR2## is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物的公式（I）ArCH.sub.2 R.sup.1（I）或其单甲基或单乙基醚（公式（I）的这些醚物可能总共不超过30个碳原子）；它们的醚，酯；酸盐；其中Ar是蒽或取代蒽环系；R.sup.1含有不超过八个碳原子，并且是一个组##STR1##其中m为0或1；R.sup.5为氢；R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-3烷基，可以选择性地被羟基取代；R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基，##STR2##是一个五元或六元饱和碳环；R.sup.10是氢，甲基或羟甲基；R.sup.11，R.sup.12和R.sup.13相同或不同，每个都是氢或甲基；R.sup.14是氢，甲基，羟基或羟甲基。
• Crysene compound
  申请人：Burroughs Wellcome Co.

  公开号：US04719048A1

  公开（公告）日：1988-01-12

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a chrysene or substituted chrysene ring system; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the ame or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物的公式（I）ArCH.sub.2R.sup.1（I）或其单甲基或单乙基醚（公式（I）的化合物包括这些醚，在总共不超过30个碳原子的情况下）;其醚，酯;酸加成盐;其中Ar是蒽或取代蒽环系统; R.sup.1含有不超过八个碳原子，是一个组##STR1##其中m为0或1; R.sup.5为氢; R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-3烷基，可以选择性地被羟基取代; R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基; ##STR2##是一个五元或六元饱和碳环; R.sup.10为氢，甲基或羟甲基; R.sup.11，R.sup.12和R.sup.13相同或不同，每个都是氢或甲基; R.sup.14为氢，甲基，羟基或羟甲基。
• Anthracene derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04719049A1

  公开（公告）日：1988-01-12

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is an anthracene or substituted anthracene ring system; R.sup.1 contains not more than eight carbon carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; --C--C-- is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及式(I) ArCH.sub.2 R.sup.1(I)的化合物，或其单甲基或单乙基醚（式(I)的化合物包括这些醚，总碳原子数不超过30个）；它们的醚、酯；酸加成盐；其中Ar是蒽或取代蒽环系；R.sup.1含有不超过八个碳原子，是一个基团##STR1##其中m为0或1；R.sup.5为氢；R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-3烷基，可选地被羟基取代；R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基；--C--C--是五元或六元饱和碳环；R.sup.10为氢，甲基或羟甲基；R.sup.11、R.sup.12和R.sup.13相同或不同，每个都是氢或甲基；R.sup.14为氢，甲基，羟基或羟甲基。